Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

Non-AIDS defining cancers (NADC) are an important cause of morbidity and mortality in HIV-positive individuals. Using data from a large international cohort of HIV-positive individuals, we described the incidence of NADC from 2004-2010, and described subsequent mortality and predictors of these. Ind...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC infectious diseases 2013-10, Vol.13 (1), p.471-471, Article 471
Hauptverfasser: Worm, Signe W, Bower, Mark, Reiss, Peter, Bonnet, Fabrice, Law, Matthew, Fätkenheuer, Gerd, d'Arminio Monforte, Antonella, Abrams, Donald I, Grulich, Andrew, Fontas, Eric, Kirk, Ole, Furrer, Hansjakob, De Wit, Stephane, Phillips, Andrew, Lundgren, Jens D, Sabin, Caroline A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 471
container_issue 1
container_start_page 471
container_title BMC infectious diseases
container_volume 13
creator Worm, Signe W
Bower, Mark
Reiss, Peter
Bonnet, Fabrice
Law, Matthew
Fätkenheuer, Gerd
d'Arminio Monforte, Antonella
Abrams, Donald I
Grulich, Andrew
Fontas, Eric
Kirk, Ole
Furrer, Hansjakob
De Wit, Stephane
Phillips, Andrew
Lundgren, Jens D
Sabin, Caroline A
description Non-AIDS defining cancers (NADC) are an important cause of morbidity and mortality in HIV-positive individuals. Using data from a large international cohort of HIV-positive individuals, we described the incidence of NADC from 2004-2010, and described subsequent mortality and predictors of these. Individuals were followed from 1st January 2004/enrolment in study, until the earliest of a new NADC, 1st February 2010, death or six months after the patient's last visit. Incidence rates were estimated for each year of follow-up, overall and stratified by gender, age and mode of HIV acquisition. Cumulative risk of mortality following NADC diagnosis was summarised using Kaplan-Meier methods, with follow-up for these analyses from the date of NADC diagnosis until the patient's death, 1st February 2010 or 6 months after the patient's last visit. Factors associated with mortality following NADC diagnosis were identified using multivariable Cox proportional hazards regression. Over 176,775 person-years (PY), 880 (2.1%) patients developed a new NADC (incidence: 4.98/1000PY [95% confidence interval 4.65, 5.31]). Over a third of these patients (327, 37.2%) had died by 1st February 2010. Time trends for lung cancer, anal cancer and Hodgkin's lymphoma were broadly consistent. Kaplan-Meier cumulative mortality estimates at 1, 3 and 5 years after NADC diagnosis were 28.2% [95% CI 25.1-31.2], 42.0% [38.2-45.8] and 47.3% [42.4-52.2], respectively. Significant predictors of poorer survival after diagnosis of NADC were lung cancer (compared to other cancer types), male gender, non-white ethnicity, and smoking status. Later year of diagnosis and higher CD4 count at NADC diagnosis were associated with improved survival. The incidence of NADC remained stable over the period 2004-2010 in this large observational cohort. The prognosis after diagnosis of NADC, in particular lung cancer and disseminated cancer, is poor but has improved somewhat over time. Modifiable risk factors, such as smoking and low CD4 counts, were associated with mortality following a diagnosis of NADC.
doi_str_mv 10.1186/1471-2334-13-471
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3852673</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534607433</galeid><sourcerecordid>A534607433</sourcerecordid><originalsourceid>FETCH-LOGICAL-b752t-7340c644b410eb3a4a719e0790c989f2d2c8407a511e13b80aad329638eb0dad3</originalsourceid><addsrcrecordid>eNqNk99v0zAQxyMEYmPwzhOyxAt7yPCPJI77gFS1wCpVTKLAq-XYTuspsTvbqdh_j6OOsk5DmhIpp_Pn-_Xp7pJlbxG8QKiuPqKCohwTUuSI5Cl-lp0eUs_vxSfZqxCuIUS0xuxldoILBCuGq9NMfXM2ny7mK6B0a6yxayCFldoHYCyIGw3mk-lkDlZxULd5Hk2vQfTaqgCEVWDrtTIyuoS7FoTB78xOdBMggHQb5yMIo-519qIVXdBv7r5n2c8vn3_MLvPl1dfFbLrMG1rimFNSQFkVRZOq0w0RhaCIaUgZlKxmLVZY1gWkokRII9LUUAhFMKtIrRuoUnyWfdr7boem10pqG73o-NabXvhb7oThxyfWbPja7TipS1xRkgzO9wabB7LL6ZKPOYhQehndocTO9mxj3H8uOz6RrufjRPg4EY4IT3Fy-XBXsnc3gw6R9yZI3XXCajeEJEhjwhXE7AloyVCJS1Qm9P0D9NoN3qbej1RNakQh-0etRae5sa1LdcrRlE9LUlSQFmTsycUjVHqU7o10Nq1Nyh8Jzo8EiYn6d1yLIQS-WH1_Onv165iFe1Z6F4LX7aHXCPLxd3isu-_uL8RB8Hf_yR8LOf81</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1458381709</pqid></control><display><type>article</type><title>Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SpringerLink Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><source>PubMed Central Open Access</source><creator>Worm, Signe W ; Bower, Mark ; Reiss, Peter ; Bonnet, Fabrice ; Law, Matthew ; Fätkenheuer, Gerd ; d'Arminio Monforte, Antonella ; Abrams, Donald I ; Grulich, Andrew ; Fontas, Eric ; Kirk, Ole ; Furrer, Hansjakob ; De Wit, Stephane ; Phillips, Andrew ; Lundgren, Jens D ; Sabin, Caroline A</creator><creatorcontrib>Worm, Signe W ; Bower, Mark ; Reiss, Peter ; Bonnet, Fabrice ; Law, Matthew ; Fätkenheuer, Gerd ; d'Arminio Monforte, Antonella ; Abrams, Donald I ; Grulich, Andrew ; Fontas, Eric ; Kirk, Ole ; Furrer, Hansjakob ; De Wit, Stephane ; Phillips, Andrew ; Lundgren, Jens D ; Sabin, Caroline A ; D:A:D Study Group ; for the D:A:D Study Group</creatorcontrib><description>Non-AIDS defining cancers (NADC) are an important cause of morbidity and mortality in HIV-positive individuals. Using data from a large international cohort of HIV-positive individuals, we described the incidence of NADC from 2004-2010, and described subsequent mortality and predictors of these. Individuals were followed from 1st January 2004/enrolment in study, until the earliest of a new NADC, 1st February 2010, death or six months after the patient's last visit. Incidence rates were estimated for each year of follow-up, overall and stratified by gender, age and mode of HIV acquisition. Cumulative risk of mortality following NADC diagnosis was summarised using Kaplan-Meier methods, with follow-up for these analyses from the date of NADC diagnosis until the patient's death, 1st February 2010 or 6 months after the patient's last visit. Factors associated with mortality following NADC diagnosis were identified using multivariable Cox proportional hazards regression. Over 176,775 person-years (PY), 880 (2.1%) patients developed a new NADC (incidence: 4.98/1000PY [95% confidence interval 4.65, 5.31]). Over a third of these patients (327, 37.2%) had died by 1st February 2010. Time trends for lung cancer, anal cancer and Hodgkin's lymphoma were broadly consistent. Kaplan-Meier cumulative mortality estimates at 1, 3 and 5 years after NADC diagnosis were 28.2% [95% CI 25.1-31.2], 42.0% [38.2-45.8] and 47.3% [42.4-52.2], respectively. Significant predictors of poorer survival after diagnosis of NADC were lung cancer (compared to other cancer types), male gender, non-white ethnicity, and smoking status. Later year of diagnosis and higher CD4 count at NADC diagnosis were associated with improved survival. The incidence of NADC remained stable over the period 2004-2010 in this large observational cohort. The prognosis after diagnosis of NADC, in particular lung cancer and disseminated cancer, is poor but has improved somewhat over time. Modifiable risk factors, such as smoking and low CD4 counts, were associated with mortality following a diagnosis of NADC.</description><identifier>ISSN: 1471-2334</identifier><identifier>EISSN: 1471-2334</identifier><identifier>DOI: 10.1186/1471-2334-13-471</identifier><identifier>PMID: 24106926</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Acquired immune deficiency syndrome ; Adult ; AIDS ; AIDS (Disease) ; Anti-HIV Agents - therapeutic use ; Antiretroviral Therapy, Highly Active ; Australia ; Cancer ; CD4 Lymphocyte Count ; Drug therapy ; Female ; France ; HIV ; HIV (Viruses) ; HIV Infections - drug therapy ; HIV Infections - mortality ; Human immunodeficiency virus ; Humans ; Incidence ; Kaplan-Meier Estimate ; Life Sciences ; Lung cancer ; Lymphomas ; Male ; Microbiology and Parasitology ; Middle Aged ; Mortality ; Neoplasms - mortality ; Netherlands ; Patient outcomes ; Pharmaceutical industry ; Prognosis ; Prospective Studies ; Risk factors ; Spain ; Statistics ; United Kingdom</subject><ispartof>BMC infectious diseases, 2013-10, Vol.13 (1), p.471-471, Article 471</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><rights>2013 Worm et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>Copyright © 2013 Worm et al.; licensee BioMed Central Ltd. 2013 Worm et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b752t-7340c644b410eb3a4a719e0790c989f2d2c8407a511e13b80aad329638eb0dad3</citedby><cites>FETCH-LOGICAL-b752t-7340c644b410eb3a4a719e0790c989f2d2c8407a511e13b80aad329638eb0dad3</cites><orcidid>0000-0001-5927-4178 ; 0000-0002-1849-9626</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852673/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852673/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24106926$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01101197$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Worm, Signe W</creatorcontrib><creatorcontrib>Bower, Mark</creatorcontrib><creatorcontrib>Reiss, Peter</creatorcontrib><creatorcontrib>Bonnet, Fabrice</creatorcontrib><creatorcontrib>Law, Matthew</creatorcontrib><creatorcontrib>Fätkenheuer, Gerd</creatorcontrib><creatorcontrib>d'Arminio Monforte, Antonella</creatorcontrib><creatorcontrib>Abrams, Donald I</creatorcontrib><creatorcontrib>Grulich, Andrew</creatorcontrib><creatorcontrib>Fontas, Eric</creatorcontrib><creatorcontrib>Kirk, Ole</creatorcontrib><creatorcontrib>Furrer, Hansjakob</creatorcontrib><creatorcontrib>De Wit, Stephane</creatorcontrib><creatorcontrib>Phillips, Andrew</creatorcontrib><creatorcontrib>Lundgren, Jens D</creatorcontrib><creatorcontrib>Sabin, Caroline A</creatorcontrib><creatorcontrib>D:A:D Study Group</creatorcontrib><creatorcontrib>for the D:A:D Study Group</creatorcontrib><title>Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study</title><title>BMC infectious diseases</title><addtitle>BMC Infect Dis</addtitle><description>Non-AIDS defining cancers (NADC) are an important cause of morbidity and mortality in HIV-positive individuals. Using data from a large international cohort of HIV-positive individuals, we described the incidence of NADC from 2004-2010, and described subsequent mortality and predictors of these. Individuals were followed from 1st January 2004/enrolment in study, until the earliest of a new NADC, 1st February 2010, death or six months after the patient's last visit. Incidence rates were estimated for each year of follow-up, overall and stratified by gender, age and mode of HIV acquisition. Cumulative risk of mortality following NADC diagnosis was summarised using Kaplan-Meier methods, with follow-up for these analyses from the date of NADC diagnosis until the patient's death, 1st February 2010 or 6 months after the patient's last visit. Factors associated with mortality following NADC diagnosis were identified using multivariable Cox proportional hazards regression. Over 176,775 person-years (PY), 880 (2.1%) patients developed a new NADC (incidence: 4.98/1000PY [95% confidence interval 4.65, 5.31]). Over a third of these patients (327, 37.2%) had died by 1st February 2010. Time trends for lung cancer, anal cancer and Hodgkin's lymphoma were broadly consistent. Kaplan-Meier cumulative mortality estimates at 1, 3 and 5 years after NADC diagnosis were 28.2% [95% CI 25.1-31.2], 42.0% [38.2-45.8] and 47.3% [42.4-52.2], respectively. Significant predictors of poorer survival after diagnosis of NADC were lung cancer (compared to other cancer types), male gender, non-white ethnicity, and smoking status. Later year of diagnosis and higher CD4 count at NADC diagnosis were associated with improved survival. The incidence of NADC remained stable over the period 2004-2010 in this large observational cohort. The prognosis after diagnosis of NADC, in particular lung cancer and disseminated cancer, is poor but has improved somewhat over time. Modifiable risk factors, such as smoking and low CD4 counts, were associated with mortality following a diagnosis of NADC.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adult</subject><subject>AIDS</subject><subject>AIDS (Disease)</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Australia</subject><subject>Cancer</subject><subject>CD4 Lymphocyte Count</subject><subject>Drug therapy</subject><subject>Female</subject><subject>France</subject><subject>HIV</subject><subject>HIV (Viruses)</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - mortality</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Incidence</subject><subject>Kaplan-Meier Estimate</subject><subject>Life Sciences</subject><subject>Lung cancer</subject><subject>Lymphomas</subject><subject>Male</subject><subject>Microbiology and Parasitology</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Neoplasms - mortality</subject><subject>Netherlands</subject><subject>Patient outcomes</subject><subject>Pharmaceutical industry</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Risk factors</subject><subject>Spain</subject><subject>Statistics</subject><subject>United Kingdom</subject><issn>1471-2334</issn><issn>1471-2334</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNk99v0zAQxyMEYmPwzhOyxAt7yPCPJI77gFS1wCpVTKLAq-XYTuspsTvbqdh_j6OOsk5DmhIpp_Pn-_Xp7pJlbxG8QKiuPqKCohwTUuSI5Cl-lp0eUs_vxSfZqxCuIUS0xuxldoILBCuGq9NMfXM2ny7mK6B0a6yxayCFldoHYCyIGw3mk-lkDlZxULd5Hk2vQfTaqgCEVWDrtTIyuoS7FoTB78xOdBMggHQb5yMIo-519qIVXdBv7r5n2c8vn3_MLvPl1dfFbLrMG1rimFNSQFkVRZOq0w0RhaCIaUgZlKxmLVZY1gWkokRII9LUUAhFMKtIrRuoUnyWfdr7boem10pqG73o-NabXvhb7oThxyfWbPja7TipS1xRkgzO9wabB7LL6ZKPOYhQehndocTO9mxj3H8uOz6RrufjRPg4EY4IT3Fy-XBXsnc3gw6R9yZI3XXCajeEJEhjwhXE7AloyVCJS1Qm9P0D9NoN3qbej1RNakQh-0etRae5sa1LdcrRlE9LUlSQFmTsycUjVHqU7o10Nq1Nyh8Jzo8EiYn6d1yLIQS-WH1_Onv165iFe1Z6F4LX7aHXCPLxd3isu-_uL8RB8Hf_yR8LOf81</recordid><startdate>20131009</startdate><enddate>20131009</enddate><creator>Worm, Signe W</creator><creator>Bower, Mark</creator><creator>Reiss, Peter</creator><creator>Bonnet, Fabrice</creator><creator>Law, Matthew</creator><creator>Fätkenheuer, Gerd</creator><creator>d'Arminio Monforte, Antonella</creator><creator>Abrams, Donald I</creator><creator>Grulich, Andrew</creator><creator>Fontas, Eric</creator><creator>Kirk, Ole</creator><creator>Furrer, Hansjakob</creator><creator>De Wit, Stephane</creator><creator>Phillips, Andrew</creator><creator>Lundgren, Jens D</creator><creator>Sabin, Caroline A</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QL</scope><scope>7T2</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5927-4178</orcidid><orcidid>https://orcid.org/0000-0002-1849-9626</orcidid></search><sort><creationdate>20131009</creationdate><title>Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study</title><author>Worm, Signe W ; Bower, Mark ; Reiss, Peter ; Bonnet, Fabrice ; Law, Matthew ; Fätkenheuer, Gerd ; d'Arminio Monforte, Antonella ; Abrams, Donald I ; Grulich, Andrew ; Fontas, Eric ; Kirk, Ole ; Furrer, Hansjakob ; De Wit, Stephane ; Phillips, Andrew ; Lundgren, Jens D ; Sabin, Caroline A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b752t-7340c644b410eb3a4a719e0790c989f2d2c8407a511e13b80aad329638eb0dad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adult</topic><topic>AIDS</topic><topic>AIDS (Disease)</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Australia</topic><topic>Cancer</topic><topic>CD4 Lymphocyte Count</topic><topic>Drug therapy</topic><topic>Female</topic><topic>France</topic><topic>HIV</topic><topic>HIV (Viruses)</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - mortality</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Incidence</topic><topic>Kaplan-Meier Estimate</topic><topic>Life Sciences</topic><topic>Lung cancer</topic><topic>Lymphomas</topic><topic>Male</topic><topic>Microbiology and Parasitology</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Neoplasms - mortality</topic><topic>Netherlands</topic><topic>Patient outcomes</topic><topic>Pharmaceutical industry</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Risk factors</topic><topic>Spain</topic><topic>Statistics</topic><topic>United Kingdom</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Worm, Signe W</creatorcontrib><creatorcontrib>Bower, Mark</creatorcontrib><creatorcontrib>Reiss, Peter</creatorcontrib><creatorcontrib>Bonnet, Fabrice</creatorcontrib><creatorcontrib>Law, Matthew</creatorcontrib><creatorcontrib>Fätkenheuer, Gerd</creatorcontrib><creatorcontrib>d'Arminio Monforte, Antonella</creatorcontrib><creatorcontrib>Abrams, Donald I</creatorcontrib><creatorcontrib>Grulich, Andrew</creatorcontrib><creatorcontrib>Fontas, Eric</creatorcontrib><creatorcontrib>Kirk, Ole</creatorcontrib><creatorcontrib>Furrer, Hansjakob</creatorcontrib><creatorcontrib>De Wit, Stephane</creatorcontrib><creatorcontrib>Phillips, Andrew</creatorcontrib><creatorcontrib>Lundgren, Jens D</creatorcontrib><creatorcontrib>Sabin, Caroline A</creatorcontrib><creatorcontrib>D:A:D Study Group</creatorcontrib><creatorcontrib>for the D:A:D Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Worm, Signe W</au><au>Bower, Mark</au><au>Reiss, Peter</au><au>Bonnet, Fabrice</au><au>Law, Matthew</au><au>Fätkenheuer, Gerd</au><au>d'Arminio Monforte, Antonella</au><au>Abrams, Donald I</au><au>Grulich, Andrew</au><au>Fontas, Eric</au><au>Kirk, Ole</au><au>Furrer, Hansjakob</au><au>De Wit, Stephane</au><au>Phillips, Andrew</au><au>Lundgren, Jens D</au><au>Sabin, Caroline A</au><aucorp>D:A:D Study Group</aucorp><aucorp>for the D:A:D Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study</atitle><jtitle>BMC infectious diseases</jtitle><addtitle>BMC Infect Dis</addtitle><date>2013-10-09</date><risdate>2013</risdate><volume>13</volume><issue>1</issue><spage>471</spage><epage>471</epage><pages>471-471</pages><artnum>471</artnum><issn>1471-2334</issn><eissn>1471-2334</eissn><abstract>Non-AIDS defining cancers (NADC) are an important cause of morbidity and mortality in HIV-positive individuals. Using data from a large international cohort of HIV-positive individuals, we described the incidence of NADC from 2004-2010, and described subsequent mortality and predictors of these. Individuals were followed from 1st January 2004/enrolment in study, until the earliest of a new NADC, 1st February 2010, death or six months after the patient's last visit. Incidence rates were estimated for each year of follow-up, overall and stratified by gender, age and mode of HIV acquisition. Cumulative risk of mortality following NADC diagnosis was summarised using Kaplan-Meier methods, with follow-up for these analyses from the date of NADC diagnosis until the patient's death, 1st February 2010 or 6 months after the patient's last visit. Factors associated with mortality following NADC diagnosis were identified using multivariable Cox proportional hazards regression. Over 176,775 person-years (PY), 880 (2.1%) patients developed a new NADC (incidence: 4.98/1000PY [95% confidence interval 4.65, 5.31]). Over a third of these patients (327, 37.2%) had died by 1st February 2010. Time trends for lung cancer, anal cancer and Hodgkin's lymphoma were broadly consistent. Kaplan-Meier cumulative mortality estimates at 1, 3 and 5 years after NADC diagnosis were 28.2% [95% CI 25.1-31.2], 42.0% [38.2-45.8] and 47.3% [42.4-52.2], respectively. Significant predictors of poorer survival after diagnosis of NADC were lung cancer (compared to other cancer types), male gender, non-white ethnicity, and smoking status. Later year of diagnosis and higher CD4 count at NADC diagnosis were associated with improved survival. The incidence of NADC remained stable over the period 2004-2010 in this large observational cohort. The prognosis after diagnosis of NADC, in particular lung cancer and disseminated cancer, is poor but has improved somewhat over time. Modifiable risk factors, such as smoking and low CD4 counts, were associated with mortality following a diagnosis of NADC.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>24106926</pmid><doi>10.1186/1471-2334-13-471</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-5927-4178</orcidid><orcidid>https://orcid.org/0000-0002-1849-9626</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1471-2334
ispartof BMC infectious diseases, 2013-10, Vol.13 (1), p.471-471, Article 471
issn 1471-2334
1471-2334
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3852673
source MEDLINE; DOAJ Directory of Open Access Journals; SpringerLink Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Springer Nature OA/Free Journals; PubMed Central Open Access
subjects Acquired immune deficiency syndrome
Adult
AIDS
AIDS (Disease)
Anti-HIV Agents - therapeutic use
Antiretroviral Therapy, Highly Active
Australia
Cancer
CD4 Lymphocyte Count
Drug therapy
Female
France
HIV
HIV (Viruses)
HIV Infections - drug therapy
HIV Infections - mortality
Human immunodeficiency virus
Humans
Incidence
Kaplan-Meier Estimate
Life Sciences
Lung cancer
Lymphomas
Male
Microbiology and Parasitology
Middle Aged
Mortality
Neoplasms - mortality
Netherlands
Patient outcomes
Pharmaceutical industry
Prognosis
Prospective Studies
Risk factors
Spain
Statistics
United Kingdom
title Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T12%3A17%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Non-AIDS%20defining%20cancers%20in%20the%20D:A:D%20Study--time%20trends%20and%20predictors%20of%20survival:%20a%20cohort%20study&rft.jtitle=BMC%20infectious%20diseases&rft.au=Worm,%20Signe%20W&rft.aucorp=D:A:D%20Study%20Group&rft.date=2013-10-09&rft.volume=13&rft.issue=1&rft.spage=471&rft.epage=471&rft.pages=471-471&rft.artnum=471&rft.issn=1471-2334&rft.eissn=1471-2334&rft_id=info:doi/10.1186/1471-2334-13-471&rft_dat=%3Cgale_pubme%3EA534607433%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1458381709&rft_id=info:pmid/24106926&rft_galeid=A534607433&rfr_iscdi=true